Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
French Society of Digestive Endoscopy
Age
18–90
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Patients over the age of 18
2. Patients with locally advanced, borderline resectable, or inoperable pancreatic adenocarcinoma, confirmed by histological or cytological tests and assessed through a multidisciplinary consultation.
3. Patients without evidence of metastases.
4. No prior anti-tumoral treatment.
5. World Health Organization (WHO) performance status ≤ 1.
6. Measurable tumor according to the RECIST v1.1 criteria: a tumor lesion with the largest diameter ≥ 20 mm using conventional imaging techniques or ≥ 10 mm using spiral CT scan.
7. Patient who has provided written consent.
8. Patient with no contraindications to general anesthesia.
9. Pancreatic tumor accessible via endoscopic ultrasound.
10. Patient enrolled in a social security program (beneficiary or dependent).
You may not be if
1\. Other types of non-ductal or solid pancreatic tumors, including endocrine tumors, acinar cell adenocarcinoma, cystadenocarcinoma, and malignant ampullary tumors.
2\. Presence of metastases. 3. Contraindication to treatment with 5FU, oxaliplatin, or irinotecan. 4. Patients with a tumor that could benefit from neoadjuvant treatment with radiochemotherapy or chemotherapy alone for secondary resection (decision by a multidisciplinary committee).
5\. Pre-existing neuropathy, Gilbert's disease, or known UGT1A1\*28/\*28 genotype. 6. Chronic inflammatory bowel disease. 7. Other concurrent cancers, or a history of cancer within the last 5 years, except for in situ cervical cancer that has been treated or a properly treated basal cell carcinoma or squamous cell carcinoma.
8\. Hereditary intolerance to fructose. 9. Individuals deprived of liberty or under guardianship. 10. Inability to follow up with the study due to geographical, social, or psychological reasons.
11\. Contraindication to echo-endoscopy-guided cytopuncture (coagulation disorders or previously operated stomach).
12\. Neutrophil count \< 1500/mm³. 13. Platelet count \< 70,000/mm³. 14. Patients are not effectively treated for neoplastic jaundice if present at diagnosis.
15\. Patient in an exclusion period or currently participating in another clinical research protocol.
16\. Patients are unable to understand or read the information/consent form. 17. Pregnant women or those wishing to become pregnant during the study period, or breastfeeding women.
18\. Patients with implanted pacemakers or implantable cardioverter-defibrillators (ICDs).
Clareo Health | Pilot Study of EUS-Guided Radiofrequency and FOLFIRINOX in Advanced Pancreatic Cancer (RadioFAP )
